United States - English - NLM (National Library of Medicine)

glenmark pharmaceuticals inc., usa - hydrocortisone (unii: wi4x0x7bpj) (hydrocortisone - unii:wi4x0x7bpj) - hydrocortisone 1 mg in 1 g - hydrocortisone butyrate cream, 0.1% (lipophilic) is indicated for: none. there are no adequate and well-controlled studies in pregnant women. therefore, hydrocortisone butyrate cream should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus. corticosteroids have been shown to be teratogenic in laboratory animals when administered systemically at relatively low dosage levels. some corticosteroids have been shown to be teratogenic after dermal application in laboratory animals. note: the animal multiples of human exposure calculations in this label were based on body surface area comparisons for an adult (i.e., mg/m2 /day dose comparisons) assuming 100% human percutaneous absorption of a maximum topical human dose (mthd) for hydrocortisone butyrate cream (25 g). systemic embryofetal development studies were conducted in rats and rabbits. subcutaneous doses of 0.6, 1.8 and 5.4 mg/kg/day hydrocortisone butyrate were administered to pregnant female rats during gestation days 6 to 17. in the presence of maternal toxicity, fetal effects noted at 5.4 mg/kg/day (2x mthd) included an increased incidence of ossification variations and unossified sternebra. no treatment-related effects on embryofetal toxicity or teratogenicity were noted at doses of 5.4 and 1.8 mg/kg/day, respectively (2x mthd and 0.7x mthd, respectively). subcutaneous doses of 0.1, 0.2 and 0.3 mg/kg/day hydrocortisone butyrate were administered to pregnant female rabbits during gestation days 7 to 20. an increased incidence of abortion was noted at 0.3 mg/kg/day (0.2x mthd). in the absence of maternal toxicity, a dose-dependent decrease in fetal body weight was noted at doses ≥0.1 mg/kg/day (0.1x mthd). additional indicators of embryofetal toxicity (reduction in litter size, decreased number of viable fetuses, increased post-implantation loss) were noted at doses ≥0.2 mg/kg/day (0.2x mthd). additional fetal effects noted in this study included delayed ossification noted at doses ≥0.1 mg/kg/day and an increased incidence of fetal malformations (primarily skeletal malformations) noted at doses ≥0.2 mg/kg/day. a dose at which no treatment-related effects on embryofetal toxicity or teratogenicity were observed was not established in this study. additional systemic embryofetal development studies were conducted in rats and mice. subcutaneous doses of 0.1 and 9 mg/kg/day hydrocortisone butyrate were administered to pregnant female rats during gestation days 9 to 15. in the presence of maternal toxicity, an increase in fetal deaths and fetal resorptions and an increase in the number of ossifications in caudal vertebrae were noted at a dose of 9 mg/kg/day (3x mthd). no treatment-related effects on embryofetal toxicity or teratogenicity were noted at 0.1 mg/kg/day (0.1x mthd). subcutaneous doses of 0.2 and 1 mg/kg/day hydrocortisone butyrate were administered to pregnant female mice during gestation days 7 to 13. in the absence of maternal toxicity, an increased number of cervical ribs and one fetus with clubbed legs were noted at a dose of 1 mg/kg/day (0.2x mthd). no treatment-related effects on embryofetal toxicity or teratogenicity were noted at doses of 1 and 0.2 mg/kg/day, respectively (0.2x mthd and 0.1x mthd, respectively). no topical embryofetal development studies were conducted with hydrocortisone butyrate cream. however, topical embryofetal development studies were conducted in rats and rabbits with a hydrocortisone butyrate ointment formulation. topical doses of 1% and 10% hydrocortisone butyrate ointment were administered to pregnant female rats during gestation days 6 to 15 or pregnant female rabbits during gestation days 6 to 18. a dose-dependent increase in fetal resorptions was noted in rabbits (0.2 to 2x mthd) and fetal resorptions were noted in rats at the 10% hydrocortisone butyrate ointment dose (80x mthd). no treatment-related effects on embryofetal toxicity were noted at the 1% hydrocortisone butyrate ointment dose in rats (8x mthd). a dose at which no treatment-related effects on embryofetal toxicity were observed in rabbits after topical administration of hydrocortisone butyrate ointment was not established in this study. no treatment-related effects on teratogenicity were noted at a dose of 10% hydrocortisone butyrate ointment in rats or rabbits (80x mthd and 2x mthd, respectively). a peri- and post-natal development study was conducted in rats. subcutaneous doses of 0.6, 1.8 and 5.4 mg/kg/day hydrocortisone butyrate were administered to pregnant female rats from gestation day 6 to lactation day 20. in the presence of maternal toxicity, a dose-dependent decrease in fetal weight was noted at doses ≥1.8 mg/kg/day (0.7x mthd). no treatment-related effects on fetal toxicity were noted at 0.6 mg/kg/day (0.2x mthd). a delay in sexual maturation was noted at 5.4 mg/kg/day (2x mthd). no treatment-related effects on sexual maturation were noted at 1.8 mg/kg/day. no treatment-related effects on behavioral development or subsequent reproductive performance were noted at 5.4 mg/kg/day. systemically administered corticosteroids appear in human milk and could suppress growth, interfere with endogenous corticosteroid production, or cause other untoward effects. it is not known whether topical administration of corticosteroids could result in sufficient systemic absorption to produce detectable quantities in human milk. because many drugs are excreted in human milk, caution should be exercised when hydrocortisone butyrate cream is administered to a nursing woman. safety and efficacy in pediatric patients below 3 months of age have not been established. because of higher skin surface-to-body-mass ratios, pediatric patients are at a greater risk than adults of hpa axis suppression when they are treated with topical corticosteroids [see warnings and precautions (5.1)] . they are therefore also at a greater risk of glucocorticosteroid insufficiency after withdrawal of treatment and of cushing’s syndrome while on treatment. eighty-six (86) pediatric subjects (between 5 months and 18 years of age) with moderate to severe atopic dermatitis affecting at least 25% of body surface area (bsa) treated with hydrocortisone butyrate cream three times daily for up to 4 weeks were assessed for hpa axis suppression in two separate studies. the disease severity (moderate to severe atopic dermatitis) and the dosing regimen (three times daily) in these hpa axis studies were different from the subject population (mild to moderate atopic dermatitis) and the dosing regimen (two times daily) for which hydrocortisone butyrate cream is indicated in this population. five of the 82 evaluable subjects (6.1%) demonstrated evidence of suppression, where the criterion for defining hpa axis suppression was a serum cortisol level of less than or equal to 18 micrograms per deciliter after cosyntropin stimulation. suppressed subjects ranged in age from 5 months to 16 years and, at the time of enrollment, had 25% to 95% bsa involvement. these subjects did not demonstrate any clinical signs or symptoms despite evidence of hpa axis suppression. at the first follow up visit, approximately one month after the conclusion of treatment, cosyntropin stimulation results of all subjects had returned to normal, with the exception of one subject. this last subject recovered adrenal function by 65 days post-treatment. cushing’s syndrome, linear growth retardation, delayed weight gain, and intracranial hypertension have also been reported in pediatric patients receiving topical corticosteroids. manifestations of adrenal suppression in pediatric patients include low plasma cortisol levels to an absence of response to acth stimulation. manifestations of intracranial hypertension include bulging fontanelles, headaches, and bilateral papilledema. clinical studies of hydrocortisone butyrate cream did not include sufficient numbers of subjects aged 65 and over to determine whether they respond differently from younger subjects.

United States - English - NLM (National Library of Medicine)

physicians total care, inc. - hydrocortisone valerate (unii: 68717p8fuz) (hydrocortisone - unii:wi4x0x7bpj) - hydrocortisone valerate 2 mg in 1 g - hydrocortisone valerate cream usp, 0.2% and hydrocortisone valerate ointment usp, 0.2% are medium potency corticosteroids indicated for the relief of the inflammatory and pruritic manifestations of corticosteroid responsive dermatoses in adult patients. hydrocortisone valerate cream usp, 0.2% and hydrocortisone valerate ointment usp, 0.2% are contraindicated in those patients with a history of hypersensitivity to any of the components of the preparations.

United States - English - NLM (National Library of Medicine)

taro pharmaceuticals u.s.a., inc. - hydrocortisone butyrate (unii: 05rmf7ypwn) (hydrocortisone - unii:wi4x0x7bpj) - hydrocortisone butyrate 1 mg in 1 ml - hydrocortisone butyrate ointment, 0.1% and hydrocortisone butyrate cream usp, 0.1% are indicated for the relief of the inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses. hydrocortisone butyrate topical solution, 0.1% is indicated for the relief of the inflammatory and pruritic manifestations of seborrheic dermatitis. none.

United States - English - NLM (National Library of Medicine)

greenstone llc - hydrocortisone (unii: wi4x0x7bpj) (hydrocortisone - unii:wi4x0x7bpj) - hydrocortisone 5 mg - hydrocortisone tablets are indicated in the following conditions. primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the first choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy mineralocorticoid supplementation is of particular importance) congenital adrenal hyperplasia non suppurative thyroiditis hypercalcemia associated with cancer as adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in: psoriatic arthritis rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy) ankylosing spondylitis acute and subacute bursitis acute nonspecific tenosynovitis acute gouty arthritis post-traumatic osteoarthritis synovitis of osteoarthritis epicondylitis during an exacerbation or as maintenance therapy in selected cases of: systemic lupus erythematosus systemic dermatomyositis (polymyositis) acute rheumatic carditis pemphigus bullous dermatitis herpetiformis severe erythema multiforme (stevens-johnson syndrome) exfoliative dermatitis mycosis fungoides severe psoriasis severe seborrheic dermatitis control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment: seasonal or perennial allergic rhinitis serum sickness bronchial asthma contact dermatitis atopic dermatitis drug hypersensitivity reactions severe acute and chronic allergic and inflammatory processes involving the eye and its adnexa such as: allergic conjunctivitis keratitis allergic corneal marginal ulcers herpes zoster ophthalmicus iritis and iridocyclitis chorioretinitis anterior segment inflammation diffuse posterior uveitis and choroiditis optic neuritis sympathetic ophthalmia symptomatic sarcoidosis loeffler's syndrome not manageable by other means berylliosis fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy aspiration pneumonitis idiopathic thrombocytopenic purpura in adults secondary thrombocytopenia in adults acquired (autoimmune) hemolytic anemia erythroblastopenia (rbc anemia) congenital (erythroid) hypoplastic anemia for palliative management of: leukemias and lymphomas in adults acute leukemia of childhood to induce a diuresis or remission of proteinuria in the nephrotic syndrome, without uremia, of the idiopathic type or that due to lupus erythematosus. to tide the patient over a critical period of the disease in: ulcerative colitis regional enteritis tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy trichinosis with neurologic or myocardial involvement systemic fungal infections and known hypersensitivity to components

United States - English - NLM (National Library of Medicine)

ani pharmaceuticals, inc. - hydrocortisone (unii: wi4x0x7bpj) (hydrocortisone - unii:wi4x0x7bpj) - hydrocortisone 100 mg in 60 ml - hydrocortisone rectal suspension, usp is indicated as adjunctive therapy in the treatment of ulcerative colitis, especially distal forms, including ulcerative proctitis, ulcerative proctosigmoiditis, and left-sided ulcerative colitis. it has proved useful also in some cases involving the transverse and ascending colons. systemic fungal infections; and ileocolostomy during the immediate or early post-operative period.

United States - English - NLM (National Library of Medicine)

stat rx usa llc - hydrocortisone (unii: wi4x0x7bpj) (hydrocortisone - unii:wi4x0x7bpj) - hydrocortisone 20 mg - - endocrine disorders   primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the first choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy mineralocorticoid supplementation is of particular importance)   congenital adrenal hyperplasia   nonsuppurative thyroiditis   hypercalcemia associated with cancer - rheumatic disorders   as adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in:   psoriatic arthritis   rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy):   ankylosing spondylitis   acute and subacute bursitis   acute nonspecific tenosynovitis   acute gouty arthritis   post-traumatic osteoarthritis   synovitis or osteoarthritis   epicondylitis - collagen diseases   during an exacerbation or as maintenance therapy in selected cases of:   systemic lupus erythematosus

United States - English - NLM (National Library of Medicine)

physicians total care, inc. - hydrocortisone (unii: wi4x0x7bpj) (hydrocortisone - unii:wi4x0x7bpj) - hydrocortisone 20 mg - - endocrine disorders   primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the first choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy mineralocorticoid supplementation is of particular importance)   congenital adrenal hyperplasia   nonsuppurative thyroiditis   hypercalcemia associated with cancer - rheumatic disorders   as adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in:   psoriatic arthritis   rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy):   ankylosing spondylitis   acute and subacute bursitis   acute nonspecific tenosynovitis   acute gouty arthritis   post-traumatic osteoarthritis   synovitis or osteoarthritis   epicondylitis - collagen diseases   during an exacerbation or as maintenance therapy in selected cases of:   systemic lupus erythematosus

United States - English - NLM (National Library of Medicine)

west-ward pharmaceuticals corp - hydrocortisone (unii: wi4x0x7bpj) (hydrocortisone - unii:wi4x0x7bpj) - hydrocortisone 5 mg - hydrocortisone tablets, usp are indicated in the following conditions: 1.   endocrine disorders primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the first choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy mineralocorticoid supplementation is of particular importance) congenital adrenal hyperplasia nonsuppurative thyroiditis hypercalcemia associated with cancer 2. rheumatic disorders as adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in: psoriatic arthritis rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy) ankylosing spondylitis acute and subacute bursitis acute nonspecific tenosynovitis acute gouty arthritis post-traumatic osteoarthritis synovitis of osteoarthritis epicondylitis 3.   collagen diseases during an exacerbation or as maintenance therapy in selected cases of:

United States - English - NLM (National Library of Medicine)

par pharmaceutical - hydrocortisone (unii: wi4x0x7bpj) (hydrocortisone - unii:wi4x0x7bpj) - hydrocortisone 5 mg - hydrocortisone tablets, usp are indicated in the following conditions. - endocrine disorders primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the first choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy mineralocorticoid supplementation is of particular importance) congenital adrenal hyperplasia nonsuppurative thyroiditis hypercalcemia associated with cancer primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the first choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy mineralocorticoid supplementation is of particular importance) congenital adrenal hyperplasia nonsuppurative thyroiditis hypercalcemia associated with cancer - rheumatic disorders as adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in: psoriatic arthritis rheumatoid arthritis, including juvenile rheumatoid ar

United States - English - NLM (National Library of Medicine)

lineage therapeutics inc - hydrocortisone (unii: wi4x0x7bpj) (hydrocortisone - unii:wi4x0x7bpj) - hydrocortisone 5 mg - hydrocortisone tablets are indicated in the following conditions. primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the first choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy mineralocorticoid supplementation is of particular importance) congenital adrenal hyperplasia non suppurative thyroiditis hypercalcemia associated with cancer as adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in: psoriatic arthritis rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy) ankylosing spondylitis acute and subacute bursitis acute nonspecific tenosynovitis acute gouty arthritis post-traumatic osteoarthritis synovitis of osteoarthritis epicondylitis during an exacerbation or as maintenance therapy in selected cases of: systemic lupus erythematosus systemic dermatomyositis (polymyositis) acute rheumatic